|Cat. No. 218 008||50 µg purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.|
WB: not tested yet
IP: not tested yet
ICC: not tested yet
IHC: 1 : 500 up to 1 : 1000 (see remarks) gallery
IHC-P/FFPE: 1 : 4000 gallery
|Subtype||IgG1 (κ light chain)|
|Immunogen||Synthetic peptide corresponding to AA 1 to 16 from human Abeta (UniProt Id: P05067)|
Epitop: AA 4 to 8 from human Abeta (UniProt Id: P05067)
Reacts with: mouse (P12023), human (P05067).
Other species not tested yet.
|Specificity||Specific for Abeta 38, 40, 42, 43.|
This antibody is a chimeric antibody based on the monoclonal mouse antibody NT244. The constant regions of the heavy and light chains have been replaced with rabbit specific sequences. The antibody can therefore be used with standard anti-rabbit secondary reagents. The antibody has been expressed in mammalian cells.
Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the amyloid beta-peptides (Abeta, Aβ) 1-40/42/43 and additional C- and N-terminally modified fragments of Abeta as for instance Abeta pE3 and Abeta pE11.
An additional Abeta variant, Abeta 38, is more soluble compared to other Abeta species and is not found in plaques of sporadic Alzheimer´s cases. However, it is detected in the blood-vessel walls of a subset of patients with severe cerebral amyloid angiopathy. It especially accumulates in brains of patients carrying mutations in the Abeta coding region.
Cleavage of amyloid precursor protein APP by β- and γ- secretases results in the generation of the Aβ (βA4)peptide, whereas α-secretase cleaves within the Aβ sequence and prevents the formation of Abeta from APP.